My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 414

    1.

    Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents.

    Davis SN, Johns D, Maggs D, Xu H, Northrup JH, Brodows RG.

    Diabetes Care. 2007 Nov;30(11):2767-72. Epub 2007 Jun 26.PMID: 17595353 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.

    Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG; GWAA Study Group.

    Ann Intern Med. 2005 Oct 18;143(8):559-69.PMID: 16230722 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.

    Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, Trautmann ME.

    Clin Ther. 2007 Nov;29(11):2333-48.PMID: 18158075 [PubMed - indexed for MEDLINE]Related articles

    4.

    The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.

    Zinman B, Hoogwerf BJ, Durán García S, Milton DR, Giaconia JM, Kim DD, Trautmann ME, Brodows RG.

    Ann Intern Med. 2007 Apr 3;146(7):477-85. Erratum in: Ann Intern Med. 2007 Jun 19;146(12):896. PMID: 17404349 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

    Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.

    Clin Ther. 2008 Aug;30(8):1448-60. Erratum in: Clin Ther. 2008 Oct;30(10):1937. PMID: 18803987 [PubMed - indexed for MEDLINE]Related articles

    6.

    One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial.

    Bunck MC, Diamant M, Cornér A, Eliasson B, Malloy JL, Shaginian RM, Deng W, Kendall DM, Taskinen MR, Smith U, Yki-Järvinen H, Heine RJ.

    Diabetes Care. 2009 May;32(5):762-8. Epub 2009 Feb 5.PMID: 19196887 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting.

    Yoon NM, Cavaghan MK, Brunelle RL, Roach P.

    Clin Ther. 2009 Jul;31(7):1511-23.PMID: 19695400 [PubMed - indexed for MEDLINE]Related articles

    8.

    The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes.

    Nelson P, Poon T, Guan X, Schnabel C, Wintle M, Fineman M.

    Diabetes Technol Ther. 2007 Aug;9(4):317-26.PMID: 17705687 [PubMed - indexed for MEDLINE]Related articles

    9.

    Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus.

    Sheffield CA, Kane MP, Busch RS, Bakst G, Abelseth JM, Hamilton RA.

    Endocr Pract. 2008 Apr;14(3):285-92.PMID: 18463034 [PubMed - indexed for MEDLINE]Related articles

    10.

    Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.

    Bergenstal R, Lewin A, Bailey T, Chang D, Gylvin T, Roberts V; NovoLog Mix-vs.-Exenatide Study Group.

    Curr Med Res Opin. 2009 Jan;25(1):65-75.PMID: 19210140 [PubMed - indexed for MEDLINE]Related articles

    11.

    Managed care perspective on three new agents for type 2 diabetes.

    VanDeKoppel S, Choe HM, Sweet BV.

    J Manag Care Pharm. 2008 May;14(4):363-80. Review.PMID: 18500914 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.

    Nauck MA, Duran S, Kim D, Johns D, Northrup J, Festa A, Brodows R, Trautmann M.

    Diabetologia. 2007 Feb;50(2):259-67. Epub 2006 Dec 8.PMID: 17160407 [PubMed - indexed for MEDLINE]Related articles

    13.

    Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.

    Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fineman M, Taylor K.

    Diabetes Care. 2007 Jun;30(6):1487-93. Epub 2007 Mar 12.PMID: 17353504 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis.

    Glass LC, Qu Y, Lenox S, Kim D, Gates JR, Brodows R, Trautmann M, Bergenstal RM.

    Curr Med Res Opin. 2008 Mar;24(3):639-44. Epub 2008 Jan 23.PMID: 18218179 [PubMed - indexed for MEDLINE]Related articles

    15.

    Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.

    DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD.

    Diabetes Care. 2005 May;28(5):1092-100.PMID: 15855572 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.

    Schwartz SL, Ratner RE, Kim DD, Qu Y, Fechner LL, Lenox SM, Holcombe JH.

    Clin Ther. 2008 May;30(5):858-67.PMID: 18555933 [PubMed - indexed for MEDLINE]Related articles

    17.

    Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.

    Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD.

    Diabetes Care. 2005 May;28(5):1083-91.PMID: 15855571 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.

    Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH, Taylor KL, Trautmann ME, Kim DD, Kendall DM.

    Diabetes Obes Metab. 2006 Jul;8(4):436-47.PMID: 16776751 [PubMed - indexed for MEDLINE]Related articles

    19.

    Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.

    Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD; Exenatide-113 Clinical Study Group.

    Diabetes Care. 2004 Nov;27(11):2628-35.PMID: 15504997 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin.

    Riddle M, Frias J, Zhang B, Maier H, Brown C, Lutz K, Kolterman O.

    Diabetes Care. 2007 Nov;30(11):2794-9. Epub 2007 Aug 13.PMID: 17698615 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity